FDA Draft Guidance Seeks Faster Route for Patient-Specific Gene-Editing Therapies
The FDA issued draft guidance designed to speed personalized treatments for rare genetic diseases. Shares of gene-editing companies, including Prime Medicine, rallied Wednesday.